XCSE
EMBLA
Market cap1.93bUSD
May 03, Last price
29.50DKK
Name
Ossur hf
Chart & performance
P/E
22.37
P/S
2.01
EPS
0.20
Div yield, %
—
Shrs. gr., 5y
0.20%
Rev. gr., 5y
8.89%
Revenues
964m
+12.72%
Net income
86m
+26.64%
CFO
142m
+22.20%
Dividend
Mar 13, 20200.15 DKK/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Embla Medical hf is a global enterprise dedicated to the orthopaedic sector. Its primary focus involves the conceptualization, progression, manufacturing, and international distribution of non-surgical orthopaedic solutions. The company's business activities are geographically divided into three main regions: the Americas; Europe, the Middle East, and Africa (EMEA); and the Asia-Pacific territory. Established in 1971 by Össur Kristinsson, Embla Medical hf maintains its corporate headquarters in Reykjavík, Iceland.
Related entities
Subsidiaries (2)
ÖSSUR ICELAND EHF
ÖSSUR FINANCE AG
Key people
Chairman of the Board · since 2006
Sveinn Soelvason
President and Chief Executive Officer · since 2022
Vice Chairman of the Board · since 2021
Gudny Sveinsdottir
Chief Financial Officer · since 2022
Christian Robinson
President Americas & Global Bracing · since 2024
Lukas Maerklin
Chief Operating Officer · since 2023
Olafur Gylfason
Executive Vice President - Chronic Solutions · since 2024
Conal Harte
Executive Vice President - Patient Care · since 2025
Andre Rocha
Executive Vice President - Research and Development · since 2025
Margret Fridriksdottir
Executive Vice President - People, Strategy and Sustainability · since 2022
Arne Nielsen
Director · since 2009
Alberto Esquenazi
Independent Director · since 2021
Tina Olesen
Independent Director · since 2024
Caroline Rosenstand
Independent Director · since 2024
Headquarters & legal address
5 GRJOTHALS
REYKJAVIK, 1 110
IS
REYKJAVIK, 1 110
IS
Previous name
ÖSSUR HF.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||